Sarepta Therapeutics’ (SRPT) Buy Rating Reiterated at Needham & Company LLC

Needham & Company LLC reissued their buy rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report report published on Monday morning,Benzinga reports. The brokerage currently has a $202.00 price objective on the biotechnology company’s stock.

SRPT has been the subject of a number of other reports. Robert W. Baird cut their target price on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. Jefferies Financial Group started coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 target price on the stock. Guggenheim increased their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Cantor Fitzgerald raised shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the company from $152.00 to $167.00 in a research report on Thursday, November 7th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $182.00 price objective on shares of Sarepta Therapeutics in a report on Monday, October 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $178.71.

Sarepta Therapeutics Trading Down 1.8 %

Shares of SRPT stock opened at $115.45 on Monday. Sarepta Therapeutics has a fifty-two week low of $102.15 and a fifty-two week high of $173.25. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock’s fifty day moving average is $122.73 and its two-hundred day moving average is $127.59. The firm has a market capitalization of $11.03 billion, a P/E ratio of 92.36 and a beta of 0.77.

Insiders Place Their Bets

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares in the company, valued at $738,234. This represents a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total transaction of $1,310,820.00. Following the sale, the director now owns 22,840 shares of the company’s stock, valued at $2,851,345.60. This represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of SRPT. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at about $4,771,000. Simplify Asset Management Inc. grew its position in shares of Sarepta Therapeutics by 84.6% during the third quarter. Simplify Asset Management Inc. now owns 193,010 shares of the biotechnology company’s stock worth $24,105,000 after acquiring an additional 88,474 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Sarepta Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 1,696,354 shares of the biotechnology company’s stock valued at $211,910,000 after acquiring an additional 44,306 shares during the period. Summit Partners Public Asset Management LLC raised its position in Sarepta Therapeutics by 547.9% in the 3rd quarter. Summit Partners Public Asset Management LLC now owns 138,118 shares of the biotechnology company’s stock valued at $17,250,000 after purchasing an additional 116,800 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in Sarepta Therapeutics by 1,649.8% during the 3rd quarter. Larson Financial Group LLC now owns 8,749 shares of the biotechnology company’s stock worth $1,093,000 after purchasing an additional 8,249 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.